Wild-Type TP53 Predicts Poor Prognosis in Patients with Gastric Cancer
Open Access
- 1 January 2021
- journal article
- research article
- Published by Fortune Journals in Journal of Cancer Science and Clinical Therapeutics
- Vol. 05 (01) , 134-153
Abstract
TP53 gene is often mutated in gastric cancer (GC), nonetheless its relationship with clinicopathological characteristics and prognosis is still unclear. Here, we sought to ascertain the difference in clinical phenotypes between TP53 wild-type and mutant tumors in confirmed gastric cancer patients. To this end, we analyzed TP53 mutation status of 415 TCGA GC patients in relation to their clinical and pathological features as well as prognosis. Longrank Test showed that the survival rate of gastric cancer patients with TP53 WT was significantly lower than that of TP53 mut. Compared with TP53 mut gastric cancer patients with low mRNA expression, TP53 WT patients with low mRNA expression have lower overall survival rate. The death risk of TP53 WT gastric cancer patients is 1.395 times that of TP53 mut gastric cancer patients. The death risk of TP53 mut gastric cancer patients is not related to age, and advanced age is not a risk factor. However, the death risk of TP53 WT patients with gastric cancer increases with age, and the death risk of patients over 70 years old is 1.899 times that of patients under 60 years old. These results suggest that the prognosis of elderly gastric cancer patients with TP53 WT is worse. Conclusion: our results indicate that the status of TP53 mutation in GC is significantly correlated with clinical or molecular categories and that the prognosis of GC patients with WT TP53 is worse than that of patients with mutant TP53. Therefore, our data emphasize the importance of distinguishing TP53 WT to predict poor overall survival and relapse-free survival in patients with GC.Keywords
This publication has 31 references indexed in Scilit:
- Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registryGastric Cancer, 2012
- p53-Mediated Senescence Impairs the Apoptotic Response to Chemotherapy and Clinical Outcome in Breast CancerCancer Cell, 2012
- Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genesNature Genetics, 2012
- Prognostic value of p53 mutations in oesophageal adenocarcinoma: final results of a 15-year prospective studyEuropean Journal of Cardio-Thoracic Surgery, 2010
- Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapyBritish Journal of Cancer, 2010
- Clinical Outcomes and Correlates of TP53 Mutations and CancerCold Spring Harbor Perspectives in Biology, 2009
- TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical UseCold Spring Harbor Perspectives in Biology, 2009
- Primary and Compensatory Roles for RB Family Members at Cell Cycle Gene Promoters That Are Deacetylated and Downregulated in Doxorubicin-Induced Senescence of Breast Cancer CellsMolecular and Cellular Biology, 2006
- Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein–Barr virusCancer, 2006
- TP53 and gastric carcinoma: A reviewHuman Mutation, 2003